UK-78282
UK-78282 is a KV1.3 channel inhibitor with an IC50 value of 0.20 μM and a Kd of 0.39 μM. UK-78282 also inhibits the Kv1.4 Potassium Channel. UK-78282 blocks KV1.3 in a use-dependent manner and inhibits human T lymphocyte activation by regulating the cell cycle. UK-78282 can be used in research related to mental disorders, such as depression and schizophrenia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 191217-42-2
- 分子式: C29H35NO2
- 分子量:429.59
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
[1]|
Kv1.3 0.2 μM (IC50) |
Kv1.4 |
IL-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L929 | IC50 |
200 nM
Compound: UK-78282
|
Inhibition of Kv1.3 expressed in mouse L929 cells exposed to depolarizing step pulses from -80 mV to +40 mV by whole cell patch clamp method
Inhibition of Kv1.3 expressed in mouse L929 cells exposed to depolarizing step pulses from -80 mV to +40 mV by whole cell patch clamp method
|
[PMID: 23084278] |
| T-cell | IC50 |
0.2 μM
Compound: UK-78282
|
In vitro inhibition of human T-cells voltage-gated potassium channel subunit Kv1.3
In vitro inhibition of human T-cells voltage-gated potassium channel subunit Kv1.3
|
10.1016/S0960-894X(97)00163-7 |
| T-cell line | IC50 |
0.4 μM
Compound: 14a
|
In vitro inhibitory potency against human T-cells Rb efflux
In vitro inhibitory potency against human T-cells Rb efflux
|
10.1016/S0960-894X(97)00163-7 |
体外実験
UK‑78282 blocks Kv1.3 channel function in various cell models. Under acute administration conditions, this compound blocks native Kv1.3 channels in human peripheral blood T lymphoblasts (IC50 = 202 nM), recombinant Kv1.3 channels in L929 cells (IC50 = 280 nM), and Kv1.3 channels in RBL cells (IC50 = 333 nM); it inhibits Kv1.3-mediated 86Rb efflux in human T cells (IC50 = 0.4 μM); and it inhibits the binding of 125I‑ChTX to Kv1.3 expressed in HeLa cells (IC50 = 0.7 μM)[1].
UK‑78282 produces use-dependent block of Kv1.3 channels in human peripheral blood T lymphoblasts; the longer the duration of depolarizing pulses, the faster the establishment of steady-state block. Maintaining the holding potential at -50 mV to increase the proportion of C-type inactivated channels enhances the blocking efficacy of this compound[1].
UK-78282 binds to an internal site of the Kv1.3 channel in human peripheral blood T lymphoblasts. This site overlaps with the binding site of verapamil, but does not overlap with the binding sites of extracellular ChTX or intracellular TEA[1].
UK-78282 exhibits selectivity for Kv1.3 and Kv1.4 channels over other Kv family channels, with negligible activity on T cell KCa channels at concentrations up to 30 μM[1].
UK‑78282 (100 nM; ≥2 min) selectively inhibits action potential firing only in striatal projection neurons of the nucleus accumbens shell in low-motivation (lowS) rats, and slows the inactivation of their A-type potassium currents; this compound reduces the amplitude of A-type potassium currents in such neurons across three groups of rats, namely low-motivation (lowS), high-motivation (highS), and moderate-motivation (midS) rats[1].
UK‑78282 inhibits PHA-induced proliferation of purified human peripheral blood T cells (IC50 = 2.0 μM) by acting on the late G1/early S phase of the cell cycle; it also suppresses PHA-stimulated IL‑2 production (IC50 = 2.9 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 250-300 g, low/intermediate/high-motivation model via progressive ratio sucrose self-administration)[2]
-
Dosage:1 nM; 100 nM
-
Administration:i.c.v. bilateral microinfusion; 0.5 μl/side over 2 min + 1 min diffusion
-
Result:Showed no significant effect on PR performance in any motivation group at 1 nM.
Significantly increased PR breakpoints, active lever presses, and sucrose pellets earned in low-motivation rats at 100 nM.
Showed no effect on PR breakpoints, active lever presses, or sucrose pellets earned in intermediate- or high-motivation rats at 100 nM.
Significantly reduced inactive lever presses in high-motivation rats at 100 nM, though this effect was driven by a single outlier and did not alter other high-motivation outcomes.
化学情報
-
CAS 番号 191217-42-2
-
性状 Liquid (Density: 1.061±0.06 g/cm3)
-
分子量 429.59
-
分子式 C29H35NO2
-
Color Pink to red
-
SMILES
COC1=CC=C(CCCN2CCC(COC(C3=CC=CC=C3)C4=CC=CC=C4)CC2)C=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外:
DMSO : 25 mg/mL (58.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Hanson DC, et al. UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. British journal of pharmacology. 1999 Apr;126(8):1707-16. [Content Brief]
[2]. O'Donovan B, et al. Altered gating of K1.4 in the nucleus accumbens suppresses motivation for reward. eLife. 2019 Sep 05;8:e47870. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3278 mL | 11.6390 mL | 23.2780 mL | 58.1950 mL |
| 5 mM | 0.4656 mL | 2.3278 mL | 4.6556 mL | 11.6390 mL | |
| 10 mM | 0.2328 mL | 1.1639 mL | 2.3278 mL | 5.8195 mL | |
| 15 mM | 0.1552 mL | 0.7759 mL | 1.5519 mL | 3.8797 mL | |
| 20 mM | 0.1164 mL | 0.5820 mL | 1.1639 mL | 2.9098 mL | |
| 25 mM | 0.0931 mL | 0.4656 mL | 0.9311 mL | 2.3278 mL | |
| 30 mM | 0.0776 mL | 0.3880 mL | 0.7759 mL | 1.9398 mL | |
| 40 mM | 0.0582 mL | 0.2910 mL | 0.5820 mL | 1.4549 mL | |
| 50 mM | 0.0466 mL | 0.2328 mL | 0.4656 mL | 1.1639 mL |
UK-78282 関連分類
HY-113964 関連分類
Powered by Bioz